Literature DB >> 6524928

Drug targeting by drug entrapment into ultrafine compartments as carriers.

P Speiser.   

Abstract

The incorporation of drugs into vesicles is one of several technological methods for the optimization of targeted drug delivery and controlled drug targeting. The main problems will always remain: To design inert auxiliary accompanying materials in order to overcome side reactions; To use body-friendly and biodegradable macromolecular carrier materials for the therapeutic system; To miniaturize the dosage form dramatically in the submicroscopic size range in order to eliminate foreign body irritations; To develop ultrafine solid and amorphous vesicular compartments (nanocapsules, nanopellets, nanoparticles) to get stable systems with good tissue transfer and organ targeting properties The actual stand of the incorporation of drugs and biologic active material into ultrafine colloidal solid capsules is reviewed here as for instance: Immunoactive material; Fluorescent indicators in body fluids; Controlled and sustained release systems Nonspecific drug targeting of the first-order (passage through endothelial tissues); Second-order targeting (a specific transparenchymal migration), and a highly specific targeting of the third-order (transcellular passage, especially lysosomal transports). Examples for some of these applications are given. It can be shown that such ultrafine vesiculated capsules offer some advantages when applied parenterally, but also partly for oral application. In the future, still more studies are necessary finally to clarify the importance and practical use of such ultrafine targeting carriers.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6524928     DOI: 10.1007/bf02783754

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  16 in total

1.  New adjuvants on a polymethylmethacrylate base.

Authors:  J Kreuter; P P Speiser
Journal:  Infect Immun       Date:  1976-01       Impact factor: 3.441

2.  The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies.

Authors:  R Levy; E Hurwitz; R Maron; R Arnon; M Sela
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701

Review 3.  Commentary. Lysosomotropic agents.

Authors:  C de Duve; T de Barsy; B Poole; A Trouet; P Tulkens; F Van Hoof
Journal:  Biochem Pharmacol       Date:  1974-09-15       Impact factor: 5.858

4.  Morphological observations on the cellular and subcellular destination of intravenously administered liposomes.

Authors:  A W Segal; E J Wills; J E Richmond; G Slavin; C D Black; G Gregoriadis
Journal:  Br J Exp Pathol       Date:  1974-08

5.  Chemotherapy through lysosomes with a DNA-daunorubicin complex.

Authors:  A Trouet; D Deprez-de Campeneere; C De Duve
Journal:  Nat New Biol       Date:  1972-09-27

6.  Distribution and elimination of poly(methyl-2-14C-methacrylate) nanoparticle radioactivity after injection in rats and mice.

Authors:  J Kreuter; U Täuber; V Illi
Journal:  J Pharm Sci       Date:  1979-11       Impact factor: 3.534

7.  Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles.

Authors:  P Couvreur; B Kante; L Grislain; M Roland; P Speiser
Journal:  J Pharm Sci       Date:  1982-07       Impact factor: 3.534

8.  Toxicity of polyalkylcyanoacrylate nanoparticles I: Free nanoparticles.

Authors:  B Kante; P Couvreur; G Dubois-Krack; C De Meester; P Guiot; M Roland; M Mercier; P Speiser
Journal:  J Pharm Sci       Date:  1982-07       Impact factor: 3.534

9.  Nanocapsules: a new type of lysosomotropic carrier.

Authors:  P Couvreur; P Tulkens; M Roland; A Trouet; P Speiser
Journal:  FEBS Lett       Date:  1977-12-15       Impact factor: 4.124

10.  In vitro studies of poly(methyl methacrylate) adjuvants.

Authors:  J Kreuter; P P Speiser
Journal:  J Pharm Sci       Date:  1976-11       Impact factor: 3.534

View more
  1 in total

Review 1.  Artificial cells in medicine and biotechnology.

Authors:  T M Chang
Journal:  Appl Biochem Biotechnol       Date:  1984       Impact factor: 2.926

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.